Prevalence of sarcopenia in patients with surgical obstructive jaundice and its impact on clinical outcomes

Table 1 Distribution of diseases in jaundice and non-jaundice patients, mean ± SD/n (%)

Parameters	Jaundice (n = 383)	Non-jaundice (n = 1325)	t/χ2	P value
Age	62.04 ± 13.18	59.49 ± 13.59	-3.220	0.001
Sex			30.766	< 0.001
Male	248 (64.7)	645 (48.7)
Female	135 (35.3)	680 (51.3)
Disease			30.551	< 0.001
Benign diseases	196 (51.2)	883 (66.6)
Biliary tract disease	126 (32.9)	692 (52.2)
Liver disease	42 (11.0)	54 (4.1)
Pancreatitis	6 (1.6)	89 (6.7)
Other benign diseases	22 (5.7)	48 (3.6)
Malignant diseases	187 (48.8)	442 (33.4)
Biliary tract tumors	88 (23.0)	56 (4.2)
Liver tumors	49 (12.8)	201 (15.2)
Pancreatic tumors	26 (6.8)	57 (4.3)
Others malignant diseases	24 (6.2)	128 (9.7)
Nutritional risks	181 (47.3)	369 (27.8)	51.269	< 0.001
BMI	23.89 ± 4.17	24.77 ± 9.86	-3.163	0.002
PhA	5.12 ± 1.14	5.37 ± 0.99	-3.974	< 0.001
Hb	124.30 ± 24.07	129.62 ± 20.42	-4.572	< 0.001
LY	1.21 ± 0.67	1.65 ± 1.61	-10.593	< 0.001
Alb	36.38 ± 6.38	39.64 ± 5.73	-9.918	< 0.001
PNI	42.45 ± 7.28	47.91 ± 9.85	-12.224	< 0.001

BMI: Body mass index; PhA: Phase angle; Hb: Hemoglobin; LY: Lymphocyte count; Alb: Albumin; PNI: Prognostic nutritional index.